ArticlemBio2024
Variability in competitive fitness among environmental and clinical azole-resistant
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Antifungal Susceptibility andMicroorganisms · 2026Article
- CYP51C Y319H and H349R substitutions cannot confer azole resistance inMicrobiology spectrum · 2026Article
- Antifungal efficacy of a novel type of nanosalt against human fungal pathogens and its antifungal mechanisms.Applied microbiology and biotechnology · 2026Article
- Antimicrobial effects and mechanism of action of carboxymethyl chitosan-loaded silver ion complexes against drug-resistant Aspergillus fumigatus.Journal of microbiology (Seoul, Korea) · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Novel Genetic Diversity and Geographic Structures ofMicroorganisms · 2026Article
- Contribution of the CYP51A Y119F Mutation to Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Celebrating the fifth edition of the International Symposium on Fungal Stress - ISFUS, a decade after its 2014 debut.Fungal biology · 2025Article
- Adaptation Under Pressure: Resistance and Stress Response Interplay in ClinicalJournal of fungi (Basel, Switzerland) · 2025Article
- Moving beyond multi-triazole to multi-fungicide resistance: Broader selection of drug resistance in the human fungal pathogen Aspergillus fumigatus.PLoS pathogens · 2025Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Land use drives drug resistance in an airborne human fungal pathogen.The ISME journal · 2025Article
- Chitosan-silver nanocomposites: promising alternatives for combating azole-resistantFrontiers in cellular and infection microbiology · 2025Article
- What makesAntimicrobial agents and chemotherapy · 2024Article
- The mitochondrial protein Bcs1A regulates antifungal drug tolerance by affecting efflux pump expression in the filamentous pathogenic fungusMicrobiology spectrum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Azoles are the primary antifungal drugs used to treat infections caused by IMPORTANCE: Azole resistance in the human fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.